Navigation Links
Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
Date:6/28/2010

mary Research 140 17.3.4 Forecasts 140 17.3.5 Expert Panel Validation 142 17.4 Contact Us 143 17.5 Disclaimer 143 2.1 List of Tables

Table 1: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2001-2009 14

Table 2: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2009-2016 14

Table 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 15

Table 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 15

Table 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2001-2009 16

Table 6: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2009-2016 16

Table 7: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 17

Table 8: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 17

Table 9: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2001-2009 18

Table 10: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2009-2016 18

Table 11: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2001-2009 19

Table 12: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2009-2016 19

Table 13: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2001-2009 20

Table 14: Gastrointestinal
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... MSC , a healthcare performance improvement company advancing clinical ... Mary Beth Loesch to President and CEO. ... companies for rapid growth and market expansion, Loesch joined ... Development and Healthcare. In that role, she oversaw MSC,s ... corporate strategy and marketing. Previously, Loesch served as Senior ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... sizes and shapes, scientists now understand how they lose ... weighing any single atom. Such ultrasensitive measurements could ... and diagnostics, enabling the detection of minuscule disease-causing agents ... level. Researchers are interested in nanosized materials because ...
... ... , ... CA (Vocus) - GreenHouse announced today that on July 30, 2009 it will introduce ... a high performance ethanol fuel for cars. The first installation of the E-Fuel ...
... , , , ... Calif. and LONDON, July 27 Amgen (Nasdaq: AMGN ... companies will share commercialization of Amgen,s monoclonal antibody denosumab for postmenopausal ... product is approved in these countries. Amgen will commercialize the ...
Cached Biology Technology:1 nano-step closer to weighing a single atom 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 2GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO) 7
(Date:8/27/2014)... the greatest risk to Europe based upon a proxy ... researchers using a ,big data, approach to scientific research. ... and Global Health ranked the top 100 pathogens affecting ... a system which, they believe, will help governments across ... of infectious diseases, including as a result of climate ...
(Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and ... Annual International Conference (EMBC,14), this year being held at ... Chicago, Illinois , from Tuesday, August 26 through ... and industry professionals in science, medicine, and engineering are ... This year,s conference theme is ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... young scientists have received postdoctoral fellowships from the National ... they conduct research with the eventual aim of protecting ... mentorship from a faculty member at their home institution, ... research teams. This allows them to interact with some ...
... from a pivotal, large-scale Phase III trial, published online ... , show that the RTS,S malaria vaccine candidate can ... immunization with a control vaccine, infants (aged 6-12 weeks ... episodes of both clinical and severe malaria and had ...
... Nearly 3,000 insect scientists are expected to attend Entomology 2012, ... this November in Knoxville, TN. Members of the media who ... press pass. WHEN: November 11-14, 2012 ... WHAT: Entomology 2012 is the 60th Annual ...
Cached Biology News:Space research institute awards postdoctoral fellowships to 4 scientists 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 2RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 3RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants 4